Deschloroketamine
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
JSmol) | |
| |
|
Deschloroketamine (DXE, DCK, 2'-Oxo-PCM) is a
dissociative anesthetic[1][2] that has been sold online as a designer drug.[3][4][5][6][7] It has also been proposed for the treatment of bacterial, fungal, viral or protozoal infections and for immunomodulation at doses of 2 mg per day.[8]
History
In 2019, it became part of a group of molecules studied by the French laboratory Caulredaitens.[citation needed]
Legal status
Deschloroketamine is illegal in Latvia,[9] and is covered by blanket bans in Canada and the UK.[citation needed]
See also
- Ketamine
- 2-Fluorodeschloroketamine
- 3-Fluorodeschloroketamine
- Bromoketamine
- Methoxmetamine
- Trifluoromethyldeschloroketamine
- Rhynchophylline
References
- PMID 20138515.
- ^ US 3254124, Stevens CL, "Aminoketones and methods for their production", published 31 May 1966
- PMID 26661982.
- ^ "Alerta: descloroketamina vendida como ketamina en Barcelona" (in Spanish). Energy Control. Retrieved 2 October 2015.
- ^ Villalba J (27 March 2015). "Los efectos desconocidos de la sequía de ketamina" (in Spanish). Vice. Retrieved 2 October 2015.
- ^ Knibbs J (22 October 2015). "Party-drug testing shows its worth". The Medical Republic.
- S2CID 204975994.
- ^ DE 4409671, Preiss D, Tatar A, "Use of 2-methylamino-2-phenylcyclohexanone for the treatment of bacterial, fungal, viral or protozoal infections and for immunomodulation", published 23 May 1995
- ^ "Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem" [Regulations on Narcotic Drugs, Psychotropic Substances and Precursors Controlled in Latvia] (in Latvian). Ministry of Health of the Republic of Latvia. Archived from the original on 4 March 2016. Retrieved 29 October 2015.